
|Articles|June 3, 2022
News Roundup: May 30 to June 3
Author(s)Miranda Hester
Your weekly roundup of the latest news from Drug Topics®.
Advertisement
NCPA Announces Support for Bipartisan PBM Transparency Bill
The bill allows state attorneys general and the Federal Trade Commission the ability to initiate legal action against certain PBM business practices.
Is Cephalexin Dosing for Uncomplicated UTIs in the ED Appropriate?
While antibiotic dosing was correct, therapy duration was frequently inappropriate.
The Need for Patient-Specific Medication Optimization Systems
Medication decision support tools focused on individual patients can help pharmacists effectively analyze risk of unintended harm, identify and assess potential interventions, and facilitate longitudinal care.
No Association Between mRNA COVID-19 and Herpes Zoster Identified
Study investigators hope these results are reassuring.
Evaluating the Effectiveness of Naloxone Infusion Therapy for Opioid, Clonidine Ingestion in Children
Current data about naloxone use in pediatric populations is extrapolated from adult studies.
Advertisement
Related to this article

An abstract from the American Heart Association's Scientific Sessions 2026 reveals the continuous expansion of the GLP-1 medication class.

Matthew Crawford, PhD, of the University of Virginia, and Mario Danek of Qnovia explain what pharmacists can do now and what may come next.

The inquiry puts audit practices, including how pharmacies are selected for audit, proportionality, and pharmacy advocacy in focus.

Nolla Derm’s overseeing physician, Zaid Fadul, MD, FS, FAAFP, discusses the revolutionary AI technology that could transform how health care conducts prescribing practices.

As COVID-19 vaccine guidance shifts, new data suggest vaccinated patients face no greater clot or death risk than with other respiratory infections.

Alyssa Eisenberg, PharmD, explores technology’s emerging role in the health care environment and how the pharmacist of the future’s day-to-day tasks might evolve.

In the final portion of our discussion with Kimberly Kue-Tsemo, PharmD, she explores the key developments that could be the most significant push toward reducing pharmacy deserts.
Advertisement
Advertisement
Trending on Drug Topics
1
PBMs Must Now Disclose Fees to Employer Plans Under Final DOL Rule
2
PBM Audit Practices Under Scrutiny: What the House Inquiry Means for Independent Pharmacies
3
COVID-19 Vaccine Lowers Venous Thromboembolism, Mortality Risk
4
GLP-1s Outperform Metformin in Prediabetes Risk, MACE
5

